Please login to the form below

Not currently logged in
Email:
Password:

Synovate Healthcare appoints Paul Villa

Synovate Healthcare has appointed Paul Villa as senior vice president of payer and market access research for specialist healthcare research

Synovate Healthcare, the global specialist healthcare market research arm of Synovate, has appointed Paul Villa to the role of senior vice president of payer and market access research for its specialist healthcare research division.

Villa joins from global research-based consultancy firm Genactis, where he held the role of vice president responsible for leading US pricing and reimbursement projects. Villa brings vast knowledge of the US payer market to Synovate Healthcare, along with detailed knowledge of multiple therapy areas. He also has experience in the commercialisation and pricing of products in managed markets, which he gained in a previous marketing consultancy role.

Bob Douglas, global head of Synovate Healthcare said: "Paul's hands-on professional style and extensive and varied experience both agency and client-side make him a valuable addition to our team. I look forward to working with Paul to grow our payer research capabilities both in the US and globally."

Villa will lead a dedicated payer and market access research team and will take responsibility for delivering research-based guidance to clients on market access issues.


19th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics